Log In Get Started
Press Releases May 13, 2026 04:05 PM

Zentalis Pharmaceuticals to Participate in Upcoming Investor Conferences

Zentalis Pharmaceuticals to Present at Multiple Upcoming Investor Conferences in May and June 2026

By Derek Hwang
Share
Twitter Reddit Facebook LinkedIn
ZNTL

Zentalis Pharmaceuticals, a clinical-stage oncology company focusing on developing a first-in-class WEE1 inhibitor called azenosertib for ovarian cancer and other tumor types, announced its management team's participation in several upcoming investor conferences. These include events hosted by H.C. Wainwright, Stifel, TD Cowen, and Jefferies from May to June 2026, with live webcasts and archived presentations available on the company's website.

Zentalis Pharmaceuticals to Participate in Upcoming Investor Conferences
ZNTL
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Zentalis Pharmaceuticals is advancing late-stage development of azenosertib, a first-in-class WEE1 inhibitor targeting ovarian cancer and multiple tumor types.
  • The management team will present at four high-profile investor conferences in May and June 2026, offering updates on clinical progress and company strategy.
  • The company emphasizes its mission to provide a non-chemotherapy, orally available treatment option that enhances patient care and outcomes in oncology.
  • Sectors impacted include biotechnology, oncology therapeutics, and investment markets focused on clinical-stage biotech innovation.

SAN DIEGO, May 13, 2026 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical oncology innovator advancing late-stage development of investigational first-in-class WEE1 inhibitor azenosertib as a biomarker-driven treatment approach for ovarian cancer, today announced that members of the management team will participate in the following upcoming investor conferences:

  • H.C. Wainwright 4th Annual BioConnect Conference at Nasdaq, New York, NY. Fireside discussion, May 19, 2026, 2:30p.m. ET.

  • Stifel 2026 Virtual Oncology Forum, Virtual. Fireside discussion, May 20, 2026, 4:30p.m. ET.

  • TD Cowen 6th Annual Oncology Innovation Summit: Insights for ASCO & EHA, Virtual. Fireside discussion, May 26, 2026, 10:00a.m. ET.

  • Jefferies Global Healthcare Conference, New York, NY. Fireside discussion, June 3, 2026, 3:45p.m. ET.

Access to a live webcast of each of the H.C. Wainwright, Stifel, TD Cowen, and Jefferies events, as well as an archived recording, will be available under the “Events & Presentations” tab on the Investors & Media section of the Company’s website.

About Zentalis Pharmaceuticals
Zentalis is a clinical oncology innovator developing a treatment approach for ovarian cancer and multiple tumor types. Leveraging therapeutics development and biomarker expertise, Zentalis is advancing monotherapy and combination studies of its investigational first-in-class WEE1 inhibitor, azenosertib. Focused on translating WEE1 science into clinical practice, we aim to equip physicians with a targeted, non-chemo, orally available medicine that enhances treatment experience, choice, and outcomes. Our mission: to unburden cancer patients with more convenience and care.

For more information, please visit www.zentalis.com. Follow Zentalis on LinkedIn at www.linkedin.com/company/zentalis-pharmaceuticals

ZENTALIS® and its associated logo are trademarks of Zentalis and/or its affiliates. All website addresses and other links in this press release are for information only and are not intended to be an active link or to incorporate any website or other information into this press release.

Contact:
Aron Feingold
VP, Investor Relations & Corporate Communications
ir@zentalis.com


Risks

  • Clinical development risk remains as azenosertib is still investigational and late-stage trials results are pending, which could affect regulatory approval and commercial viability.
  • Market adoption risk exists if the drug does not demonstrate significant advantages over existing treatments or faces competition in ovarian cancer and tumor therapies.
  • Financial risk related to continued funding and investor sentiment around biotech stocks, especially if future clinical or business milestones are delayed or unmet.

More from Press Releases

Celldex Presents Long-Term Barzolvolimab Results Demonstrating Sustained Off-Treatment Improvement in Angioedema in Patients with CSU at the European Academy of Allergy and Clinical Immunology Annual Meeting Jun 14, 2026 Upstream Bio Presents New Responder Analyses Demonstrating Clinically Meaningful Improvements in CRSwNP in Significant Majority of Participants Treated with Verekitug in the Phase 2 VIBRANT Trial at EAACI 2026 Jun 14, 2026 Mineralys Therapeutics Presents Late-Breaking Data on Lorundrostat and Heart Failure Risk Biomarkers at The Endocrine Society Annual Meeting (ENDO 2026) Jun 14, 2026 Celldex Presents Positive First-in-Human Results from Phase 1 Study of Novel Bispecific CDX-622 at the European Academy of Allergy and Clinical Immunology Annual Meeting Jun 14, 2026 Legend Biotech Establishes Clinical Proof-of-Concept for LB2501, a Potential First-in-Class In Vivo CD19/CD20 Dual-Targeting CAR-T, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma Jun 14, 2026